MIRA Pharmaceuticals Submits Phase 2a Protocol for CIPN Treatment
17h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
MIRA PharmaceuticalsKetamir-2
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
MIRA Pharmaceuticals announced the submission of its Phase 2a clinical trial protocol for Ketamir-2, a novel oral ketamine derivative, targeting chemotherapy-induced peripheral neuropathy (CIPN) on 17 June 2026. The protocol submission to the central institutional review board represents a critical regulatory milestone, enabling the commencement of patient enrollment upon approval. The company's stock, MIRA, closed at $4.15 on the Nasdaq, reflecting a 3.5% gain for the week leading into the announcement.
Chemotherapy-induced peripheral neuropathy is a severe and often permanent side effect of common cancer treatments like platinum-based chemotherapeutics and taxanes, affecting an estimated 30-40% of patients. The condition represents a significant unmet medical need with no FDA-approved treatments, creating a market opportunity analysts at firms like Evaluate Pharma value at over $3 billion globally. The submission follows MIRA's successful End-of-Phase 1 meeting with the FDA in Q1 2026, which provided alignment on the proposed Phase 2a study design and primary endpoints.
Heightened investor focus on non-opioid pain management solutions provides a favorable backdrop for this development. The opioid crisis and subsequent regulatory crackdowns have accelerated demand for alternative analgesic mechanisms. The broader neuropathic pain treatment market, including conditions like diabetic neuropathy, is projected to reach $9.8 billion by 2028 according to GlobalData, drawing substantial capital into the sector.
MIRA Pharmaceuticals holds a market capitalization of approximately $185 million based on its recent share price of $4.15 and 44.6 million shares outstanding. The company reported $12.7 million in cash and equivalents as of its last quarterly filing, which management guidance suggests provides a runway through Q1 2027. The proposed Phase 2a trial will enroll 60 patients across 15 US clinical sites, with topline results expected by Q4 2027.
Trial design specifics include a primary endpoint measuring change from baseline in the Visual Analog Scale pain score at 8 weeks. Secondary endpoints will assess quality of life improvements using the EORTC QLQ-CIPN20 instrument. The trial design compares favorably to recent failed CIPN studies from competitors like Aptinyx and Metacrine, which encountered challenges with patient stratification and endpoint selection.
Peer company Vertex Pharmaceuticals, which is developing a non-opioid pain drug in a different class, trades at a market cap of $105 billion, illustrating the premium valuations achievable in this therapeutic area. The XBI Biotech ETF has gained 12% year-to-date, outperforming the broader SPX's 8% return, signaling renewed institutional interest in clinical-stage biotech.
The protocol submission directly benefits MIRA stock by de-risking the clinical pathway and potentially attracting partnership interest from larger pharmaceutical firms with oncology portfolios. Companies like Pfizer, which markets chemotherapy agents that cause CIPN, could view a successful treatment as complementary to their core cancer franchises. Johnson & Johnson, with its substantial pain management division, represents another potential strategic acquirer or licensor.
A counter-argument exists regarding the competitive landscape. Other novel mechanisms, including neuro-regenerative therapies from firms like WinSanTor, are in earlier development stages but could ultimately prove more effective at reversing nerve damage rather than merely managing pain. The ketamine derivative class also carries known side effect profiles including dissociation and potential for abuse, which regulators will scrutinize closely.
Trading flow data from DarkTick shows increased call option volume in MIRA throughout June, particularly in the January 2027 $5 strike contracts. This positioning suggests sophisticated traders are anticipating positive clinical catalysts over the next six to twelve months. Short interest remains elevated at 18% of float, indicating significant skepticism that must be overcome through concrete data readouts.
Immediate catalysts include IRB protocol approval, expected within 45-60 days of submission based on typical review timelines. First patient enrollment should follow within 30 days of approval, providing the next material operational milestone. Investors should monitor clinicaltrials.gov for the trial registration, which will provide detailed inclusion criteria and statistical analysis plan.
Key levels for MIRA stock include technical support at the 50-day moving average of $3.75 and resistance at the 52-week high of $4.89. A breakout above $5.00 on volume would signal strong institutional accumulation ahead of trial commencement. The XBI Biotech ETF at $95 represents a key psychological level; a break above $100 would indicate renewed sector risk-on sentiment.
The FDA's upcoming guidance on novel endpoint acceptance for neuropathic pain conditions, expected by Q3 2026, could impact trial design considerations across the sector. The American Society of Clinical Oncology annual meeting in June typically features presentations on supportive care therapeutics, providing a venue for competitor data releases.
Chemotherapy-induced peripheral neuropathy is nerve damage caused by cancer treatment drugs, resulting in pain, tingling, numbness, and weakness primarily in the hands and feet. The condition affects approximately 400,000 patients annually in the United States alone and can persist long after chemotherapy concludes. Current management relies on off-label use of gabapentinoids, antidepressants, and topical analgesics with limited efficacy and significant side effects.
Ketamir-2 is an oral prodrug designed to provide the NMDA receptor antagonism of ketamine while avoiding first-pass metabolism and reducing dissociative side effects. Traditional intravenous ketamine requires clinical administration and produces significant psychoactive effects that limit its utility for chronic conditions. The oral formulation aims to provide home-based treatment with improved safety and convenience profiles compared to existing options.
A successful CIPN treatment could achieve peak sales exceeding $1 billion annually in the US market alone based on prevalence rates and lack of competition. Oncology supportive care represents a high-value segment for pharmaceutical companies due to specialized reimbursement pathways and demonstrated willingness to pay for quality-of-life improvements. Successful Phase 2 data would likely trigger partnership discussions with major oncology-focused pharmaceutical companies.
MIRA's protocol submission advances a potential first-in-class treatment for a debilitating condition affecting hundreds of thousands of cancer patients annually.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.